for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Enzo Biochem, Inc.

ENZ.N

Latest Trade

3.04USD

Change

0.05(+1.67%)

Volume

91,937

Today's Range

2.81

 - 

3.13

52 Week Range

1.56

 - 

4.76

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2.99
Open
2.96
Volume
91,937
3M AVG Volume
6.52
Today's High
3.13
Today's Low
2.81
52 Week High
4.76
52 Week Low
1.56
Shares Out (MIL)
47.90
Market Cap (MIL)
145.60
Forward P/E
--
Dividend (Yield %)
--

Next Event

Enzo Biochem Inc Annual Shareholders Meeting

Latest Developments

More

Harbert Discovery Fund Says Sent Letter To Enzo Biochem's Independent Members Of Board

Enzo Biochem Receives FDA Emergency Use Authorization For Testing Pooled Samples On Three Platforms For Detection Of Coronavirus Sars-Cov-2

Enzo Biochem Reviews Position Of Institutional Shareholder Services

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Enzo Biochem, Inc.

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Industry

Healthcare Facilities

Contact Info

60 EXECUTIVE BLVD

FARMINGDALE, NY

11735

United States

+1.516.7555500

http://www.enzo.com/

Executive Leadership

Barry W. Weiner

President, Treasurer

Elazar Rabbani

Chairman of the Board, Chief Executive Officer, Secretary

David A. Bench

Chief Financial Officer, Principal Accounting Officer

Kara Cannon

Chief Commercial Officer

Dieter Schapfel

Chief Medical Director - Enzo Clinical Labs

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1.72
Price To Book (MRQ)
2.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
19.87
LT Debt To Equity (MRQ)
7.83
Return on Investment (TTM)
-22.59
Return on Equity (TTM)
-17.23

Latest News

Latest News

BRIEF-Enzo Announces Issuance Of U.S. Patent For Methods Of Treating Liver Cancer

* ENZO ANNOUNCES ISSUANCE OF U.S. PATENT FOR METHODS OF TREATING LIVER CANCER USING PROPRIETARY COMPOUND SK1-I

BRIEF-Enzo Biochem Reports Q3 Loss Per Share $0.21

* AT QUARTER-END, CASH, CASH EQUIVALENTS AND RESTRICTED CASH TOTALED $55 MILLION

BRIEF-Enzo Announces Issuance Of U.S. Patent For Methods Of Using Proprietary Compound SK1-I In Patients Exploring Options For Development As A Potential Treatment For Covid-19

* ENZO ANNOUNCES ISSUANCE OF U.S. PATENT FOR METHODS OF USING PROPRIETARY COMPOUND SK1-I IN PATIENTS; EXPLORING OPTIONS FOR DEVELOPMENT AS A POTENTIAL TREATMENT FOR COVID-19

BRIEF-Enzo Biochem On April 23, Got About $7 Million From Citibank N.A., Company S Existing Lender, Pursuant To PPP

* ENZO BIOCHEM INC - ON APRIL 23, GOT ABOUT $7 MILLION FROM CITIBANK N.A., COMPANY S EXISTING LENDER, PURSUANT TO PAYCHECK PROTECTION PROGRAM Source text: [https://bit.ly/357GGZ0] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Enzo Biochem Launches Proprietary Covid-19 Diagnostic Test

* ENZO BIOCHEM LAUNCHES PROPRIETARY COVID-19 DIAGNOSTIC TEST UNDER FDA’S EMERGENCY USE AUTHORIZATION

BRIEF-Enzo Biochem Says In March, Saw Material Decline In Laboratory Testing Volumes Due To COVID-19 Pandemic As Patients Reduced Physician Office Visits

* ENZO BIOCHEM - IN MARCH, SAW MATERIAL DECLINE IN LABORATORY TESTING VOLUMES DUE TO COVID-19 PANDEMIC AS PATIENTS REDUCED PHYSICIAN OFFICE VISITS

SCOTUS turns away Enzo plea to revisit patent enablement

The U.S. Supreme Court on Monday turned away an appeal by Enzo Biochem Inc of a ruling that invalidated some of its medical testing patents, rebuffing the company's arguments that the decision contradicted precedent and contravened the standard of proof for proving patent...

BRIEF-Enzo Biochem’S Clinical Laboratory To Launch Coronavirus (Covid-19) Testing Services Next Week

* ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK

BRIEF-Enzo Biochem Reports Q2 Loss Per Share $0.16

* AT QUARTER-END, CASH, CASH EQUIVALENT AND RESTRICTED CASH TOTALED $52 MILLION, AND WORKING CAPITAL AMOUNTED TO $48 MILLION Source text for Eikon: Further company coverage:

BRIEF-Harbert Discovery Fund Says Glass Lewis Joins ISS In Recommending Shareholders Vote Against Enzo Proposal To Increase Size Of Board

* HARBERT DISCOVERY FUND - GLASS LEWIS JOINS ISS IN RECOMMENDING SHAREHOLDERS VOTE AGAINST ENZO PROPOSAL TO INCREASE SIZE OF BOARD Source text: (http://bit.ly/2wz7WlT) Further company coverage:

BRIEF-ISS Recommends Shareholders Vote Against Enzo Proposal To Increase Size Of Board

* ISS RECOMMENDS SHAREHOLDERS VOTE AGAINST ENZO PROPOSAL TO INCREASE SIZE OF BOARD Source text for Eikon: Further company coverage:

BRIEF-Enzo Biochem Publishes Study Detailing Promising Activity Of Drug Candidate Sk1‑I In A Model Of Lupus

* ENZO BIOCHEM REPORTS PUBLICATION OF STUDY DETAILING PROMISING ACTIVITY OF DRUG CANDIDATE SK1-I IN A MODEL OF LUPUS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Enzo Biochem Announces Significant Milestone With Approval Of Proprietary Genflex Platform

* ENZO BIOCHEM ANNOUNCES SIGNIFICANT MILESTONE WITH APPROVAL OF PROPRIETARY GENFLEX PLATFORM Source text for Eikon: Further company coverage:

BRIEF-Enzo Biochem - Harbert Discovery Fund Filed Lawsuit Against Co, Members Of Board Of Directors

* ENZO BIOCHEM - HARBERT DISCOVERY FUND FILED LAWSUIT AGAINST CO, MEMBERS OF BOARD OF DIRECTORS IN U.S. DISTRICT COURT FOR SOUTHERN DISTRICT OF NEW YORK

BRIEF-Enzo Biochem Says CO Considering All Available Options For Challenging Federal Circuit Panel's Decision

* ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405

Enzo loses four Federal Circuit appeals on patents for gene-based diagnostic tests

A federal appeals court on Thursday dealt a blow to Enzo Life Sciences Inc, letting stand lower-court decisions that invalidated two of its patents for medical-testing technologies that use modified building blocks of DNA to detect and reveal disease and genetic defects.

BRIEF-Enzo Biochem Enters Settlement Agreement With Roche

* ENZO BIOCHEM INC - CO ALONG WITH ITS UNIT ENTERED INTO A SETTLEMENT AGREEMENT AS OF FEBRUARY 5, 2019 WITH ROCHE - SEC FILING

BRIEF-Enzo Biochem Says Patent Trial And Appeal Board Has Denied A Petition Filed By Hologic For Inter Partes Review

* ENZO BIOCHEM INC - PATENT TRIAL AND APPEAL BOARD HAS DENIED A PETITION FILED BY HOLOGIC FOR INTER PARTES REVIEW Source text for Eikon: Further company coverage:

BRIEF-Enzo Biochem Reports Q2 Adjusted Loss Per Share $0.04

* QTRLY LOSS PER SHARE $0.02 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Austock Group ‍Says Enzo Silverii Retires As Chief Financial Officer​

* GORDON JOSEPH WILL BE ACTING CFO Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up